Download PDF
Semin Neurol 2004; 24(1): 75-81
DOI: 10.1055/s-2004-829595
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Myasthenia Gravis: Management of Myasthenic Crisis and Perioperative Care

Vern C. Juel1
  • 1Associate Professor of Neurology, Department of Neurology, University of Virginia School of Medicine, Charlottesville, Virginia
Further Information

Publication History

Publication Date:
01 July 2004 (online)

   Buy Article Permissions and Reprints

Myasthenic crisis may be defined as respiratory failure or delayed postoperative extubation for more than 24 hours resulting from myasthenic weakness. Myasthenic crisis results from weakness of upper airway muscles leading to obstruction and aspiration, weakness of respiratory muscles leading to reduced tidal volumes, or from weakness of both muscle groups. About one-fifth of patients with myasthenia gravis experience crisis, usually within the first year of illness. Over the last four decades, prognosis from myasthenic crisis has dramatically improved from a mortality rate of 75% to the current rate of less than 5%. Common precipitating factors for myasthenic crisis include respiratory infections, aspiration, sepsis, surgical procedures, rapid tapering of immune modulation, beginning treatment with corticosteroids, exposure to drugs that may increase myasthenic weakness, and pregnancy. Myasthenic crisis should not be fatal, as long as patients receive timely respiratory support and appropriate immunotherapy to reduce myasthenic weakness of the upper airway and respiratory muscles. Myasthenic patients with oropharyngeal or respiratory muscle weakness should receive preoperative plasma exchange or intravenous immunoglobulin therapy to a minimal level of weakness to prevent postoperative complications.

KEYWORDS

Myasthenia gravis - myasthenic crisis - respiratory failure

REFERENCES

  • 1 Wilks S. On cerebritis, hysteria, and bulbar paralysis.  Guys Hosp Rep. 1877;  22 7-55
    PubMedGoogle Scholar
  • 2 Keesey J C. Myasthenia Gravis: An Illustrated History. Roseville, CA; Publishers Design Group 2002
    Google Scholar
  • 3 Bedlack R S, Sanders D B. On the concept of myasthenic crisis.  J Clin Neuromusc Dis. 2002;  4 40-42
    PubMedGoogle Scholar
  • 4 Tether J E. Management of myasthenic and cholinergic crises.  Am J Med. 1955;  19 740-742
    PubMedGoogle Scholar
  • 5 Ashworth B, Hunter A R. Respiratory failure in myasthenia gravis.  Proc R Soc Med. 1971;  64 489-490
    PubMedGoogle Scholar
  • 6 Gracey D R, Divertie M B, Howard F M. Mechanical ventilation for respiratory failure in myasthenia gravis: two-year experience with 22 patients.  Mayo Clin Proc. 1983;  58 597-602
    PubMedGoogle Scholar
  • 7 Thomas C E, Mayer S A, Gungor Y et al.. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation.  Neurology. 1997;  48 1253-1260
    CrossrefPubMedGoogle Scholar
  • 8 Sellman M S, Mayer R F. Treatment of myasthenic crisis in late life.  South Med J. 1985;  78 1208-1210
    PubMedGoogle Scholar
  • 9 Donaldson D H, Ansher M, Horan S, Rutherford R B, Ringel S P. The relationship of age to outcome in myasthenia gravis.  Neurology. 1990;  40 786-790
    PubMedGoogle Scholar
  • 10 Oosterhuis H J. The natural course of myasthenia gravis: a long term follow up study.  J Neurol Neurosurg Psychiatry. 1989;  52 1121-1127
    CrossrefPubMedGoogle Scholar
  • 11 Garrity E R. Respiratory failure due to disorders of the chest wall and respiratory muscles. In: MacDonnell KF, Fahey PJ, Segal MS Respiratory Intensive Care. Boston; Little Brown 1987: 312-320
    Google Scholar
  • 12 Mier-Jedrzejowicz A K, Brophy C, Green M. Respiratory muscle function in myasthenia gravis.  Am Rev Respir Dis. 1988;  138 867-873
    PubMedGoogle Scholar
  • 13 Borel C O, Teitelbaum J S, Hanley D F. Ventilatory failure and carbon dioxide response in ventilatory failure due to myasthenia gravis and Guillain-Barre syndrome.  Crit Care Med. 1993;  21 1717-1726
    PubMedGoogle Scholar
  • 14 Putman M T, Wise R A. Myasthenia gravis and upper airway obstruction.  Chest. 1996;  109 400-404
    CrossrefPubMedGoogle Scholar
  • 15 Cridge P B, Allegra J, Gerhard H. Myasthenic crisis presenting as isolated vocal cord paralysis.  Am J Emerg Med. 2000;  18 232-233
    CrossrefPubMedGoogle Scholar
  • 16 Schmidt-Nowara W W, Marder E J, Feil P A. Respiratory failure in myasthenia gravis due to vocal cord paresis.  Arch Neurol. 1984;  41 567-568
    PubMedGoogle Scholar
  • 17 Rabinstein A A, Wijdicks E FM. Warning signs of imminent respiratory failure in neurological patients.  Semin Neurol. 2003;  23 97-104
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Rieder P, Louis M, Jolliet P, Chevrolet J C. The repeated measurement of vital capacity is a poor predictor of the need for mechanical ventilation in myasthenia gravis.  Intensive Care Med. 1995;  21 663-668
    CrossrefPubMedGoogle Scholar
  • 19 Juel V C, Bleck T P. Neuromuscular disorders in critical care. In: Shoemaker WC, Ayers SM, Grenvik ANA, Holbrook PR Textbook of Critical Care, 4th ed. New York; W.B. Saunders 2000: 1886-1894
    Google Scholar
  • 20 Rabinstein A, Wijdicks E FM. BiPAP in acute respiratory failure due to myasthenic crisis may prevent intubation.  Neurology. 2002;  59 1647-1649
    CrossrefPubMedGoogle Scholar
  • 21 Mayer S A. Intensive care of the myasthenic patient.  Neurology. 1997;  48(suppl 5) S70-S75
    CrossrefPubMedGoogle Scholar
  • 22 Varelas P N, Chua H C, Natterman J et al.. Ventilatory care in myasthenia gravis crisis: assessing the baseline adverse event rate.  Crit Care Med. 2002;  30 2663-2668
    PubMedGoogle Scholar
  • 23 Bosch E P, Subbiah B, Ross M A. Cholinergic crisis after conventional doses of anticholinesterase medications in chronic renal failure.  Muscle Nerve. 1991;  14 1036-1037
    PubMedGoogle Scholar
  • 24 Borel C O. Management of myasthenic crisis: continuous anticholinesterase infusions.  Crit Care Med. 1993;  21 821-822
    PubMedGoogle Scholar
  • 25 Pinching A J, Peters D K. Remission of myasthenia gravis following plasma exchange.  Lancet. 1976;  2(8000) 1373-1376
    PubMedGoogle Scholar
  • 26 Dau P C, Lindstrom J M, Cassel C K et al.. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.  N Engl J Med. 1977;  297 1134-1140
    CrossrefPubMedGoogle Scholar
  • 27 Kornfield P, Ambinder E P, Papatestas A E, Bender A N, Genkins G. Plasmapheresis in myasthenia gravis: controlled study [letter].  Lancet. 1979;  2 629
    PubMedGoogle Scholar
  • 28 Antozzi C, Gemma M, Regi B et al.. A short plasma exchange protocol is effective in severe myasthenia gravis.  J Neurol. 1991;  238 103-107
    CrossrefPubMedGoogle Scholar
  • 29 Gracey D R, Howard F M, Divertie M B. Plasmapheresis in the treatment of ventilator-dependent myasthenia gravis patients: report of four cases.  Chest. 1984;  85 739-743
    PubMedGoogle Scholar
  • 30 Qureshi A I, Choundry M A, Akbar M S et al.. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.  Neurology. 1999;  52 629-632
    CrossrefPubMedGoogle Scholar
  • 31 Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis.  Ann Neurol. 1997;  41 789-796
    CrossrefPubMedGoogle Scholar
  • 32 Stricker R B, Kwiatkowska B J, Habis J A, Kiprov D D. Myasthenic crisis: response to plasmapheresis following failure of intravenous gamma-globulin.  Arch Neurol. 1993;  50 837-840
    CrossrefPubMedGoogle Scholar
  • 33 Huang C-S, Hsu H-S, Kao K-P, Huang M-H, Huang B-S. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis.  Acta Neurol Scand. 2003;  108 136-138
    CrossrefPubMedGoogle Scholar
  • 34 Saltis L M, Martin B R, Traeger S M, Bonfiglio M F. Continuous infusion of pyridostigmine in the management of myasthenic crisis.  Crit Care Med. 1993;  21 938-940
    CrossrefPubMedGoogle Scholar
  • 35 Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis.  Crit Care Med. 1997;  25 1228-1235
    CrossrefPubMedGoogle Scholar
  • 36 Mayer S A, Thomas C E. Therapy of myasthenic crisis.  Crit Care Med. 1998;  26 1136-1137
    PubMedGoogle Scholar
  • 37 Howard J F. Adverse drug effects on neuromuscular transmission.  Semin Neurol. 1990;  10 89-102
    PubMedGoogle Scholar
  • 38 Younger D S, Braun N MT, Jaretzki A, Penn A S, Lovelace R E. Myasthenia gravis: determinants for independent ventilation after transsternal thymectomy.  Neurology. 1984;  34 336-340
    PubMedGoogle Scholar
  • 39 Jaretzki A, Aarli J A, Kaminski H J, Phillips L H, Sanders D B. Preoperative preparation of patients with myasthenia gravis forestalls postoperative respiratory complications after thymectomy.  Ann Thorac Surg. 2003;  75 1068
    CrossrefPubMedGoogle Scholar
  • 40 Leventhal S R, Orkin F K, Hirsh R A. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis.  Anesthesiology. 1980;  53 26-30
    PubMedGoogle Scholar
  • 41 d'Empaire G, Hoaglin D C, Perlo V P et al.. Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis.  J Thorac Cardiovasc Surg. 1985;  89 592-596
    PubMedGoogle Scholar
  • 42 Cumming W JK, Hudgson P. The role of plasma phoresis in preparing patients with myasthenia for thymectomy [abstract].  Muscle Nerve. 1986;  9 S155
    PubMedGoogle Scholar
  • 43 Kirsch J R, Diringer M N, Borel C O et al.. Preoperative lumbar epidural morphine improves postoperative analgesia and ventilatory function after transsternal thymectomy in patients with myasthenia gravis.  Crit Care Med. 1991;  19 1474-1479
    PubMedGoogle Scholar

Vern C JuelM.D. 

P.O. Box 800394, University of Virginia Health System, Charlottesville, VA 22908-0394

      >